煙臺東誠藥(yao)(yao)(yao)業集團股份(fen)有(you)限公(gong)司(si)(前身(shen)為煙臺東誠生(sheng)化(hua)股份(fen)有(you)限公(gong)司(si))成(cheng)立于1998年,2012年5月在深(shen)交所上(shang)市(shi)(股票代碼002675)。歷經20余年的發展,東誠藥(yao)(yao)(yao)業現已成(cheng)為一(yi)家覆蓋生(sheng)化(hua)原(yuan)料藥(yao)(yao)(yao)、化(hua)藥(yao)(yao)(yao)、中成(cheng)藥(yao)(yao)(yao)、核藥(yao)(yao)(yao)四大領域(yu),融藥(yao)(yao)(yao)品研發、生(sheng)產(chan)、銷(xiao)售于一(yi)體的大型(xing)制藥(yao)(yao)(yao)企(qi)業集團。
集團控股煙臺東誠(cheng)(cheng)北方制藥(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、煙臺東誠(cheng)(cheng)大洋(yang)制藥(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、臨(lin)沂東誠(cheng)(cheng)東源(yuan)生物(wu)工程有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、中泰(tai)生物(wu)制品有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、東誠(cheng)(cheng)國(guo)際(香港(gang))有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、成都云(yun)克藥(yao)業有(you)(you)限(xian)(xian)(xian)(xian)責任公(gong)(gong)(gong)司(si)(si)(si)(si)、上海(hai)欣科(ke)醫(yi)(yi)藥(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、上海(hai)益(yi)泰(tai)醫(yi)(yi)藥(yao)科(ke)技有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、南京江原安迪(di)科(ke)正電(dian)子研究發(fa)展有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)等40多家分(fen)子公(gong)(gong)(gong)司(si)(si)(si)(si),集團在北京、上海(hai)、南京設立研發(fa)分(fen)支機構和辦(ban)事(shi)處,擁(yong)有(you)(you)員(yuan)工近兩千(qian)人。
東誠藥(yao)業(ye)作(zuo)為國內(nei)前沿的(de)生化原(yuan)料藥(yao)生產(chan)(chan)企業(ye),核心(xin)產(chan)(chan)品肝素(su)鈉(na)及硫酸軟骨素(su)憑借優質(zhi)質(zhi)量,贏得了(le)眾多(duo)的(de)國際機構(gou)認證,產(chan)(chan)品90%以上銷(xiao)往歐洲、美洲、亞太等全球40多(duo)個國家和地區,與眾多(duo)國際知名藥(yao)企建立了(le)穩定的(de)合作(zuo)關系。
東誠藥(yao)業(ye)(ye)(ye)不斷(duan)強化(hua)制劑(ji)業(ye)(ye)(ye)務(wu),制劑(ji)產品覆蓋(gai)心血管、抗腫瘤(liu)、泌(mi)尿、骨科等治療(liao)(liao)領(ling)域。近年(nian)來,公司(si)高起(qi)點進(jin)入高技術壁壘和高成長(chang)性的核醫藥(yao)行業(ye)(ye)(ye),相(xiang)繼并購國內多家核藥(yao)企業(ye)(ye)(ye),完成從診斷(duan)用核藥(yao)到治療(liao)(liao)用核藥(yao)的全產業(ye)(ye)(ye)鏈布局,奠(dian)定了公司(si)在(zai)中國核醫藥(yao)領(ling)域的前沿地(di)位。
東誠藥業不斷加大(da)科研投入,致(zhi)力自主創新,引(yin)進泰(tai)山學者(zhe)、973科學家等高素(su)質人才。通過建立(li)廣泛的產學研合作網絡,實(shi)現新技術的引(yin)進轉化,通過創新驅動(dong)帶領企業發展。
在(zai)“立足東(dong)方,誠諾健康(kang)”企業(ye)(ye)(ye)使命指(zhi)引下(xia),東(dong)誠藥(yao)業(ye)(ye)(ye)將深化資源整合、優(you)化產(chan)業(ye)(ye)(ye)結(jie)構(gou)、不(bu)斷提(ti)升企業(ye)(ye)(ye)創新能(neng)力與核心競爭力,以“全球肝素專(zhuan)家,中國核藥(yao)領軍企業(ye)(ye)(ye)”為目標,向著成長為專(zhuan)業(ye)(ye)(ye)領域(yu)前(qian)沿的、持(chi)續創造優(you)異價值的制藥(yao)企業(ye)(ye)(ye)不(bu)斷邁進(jin)。